Skip to main content
Top
Published in: BMC Medicine 1/2014

Open Access 01-12-2014 | Editorial

Vascular risk factors and Alzheimer’s disease

Authors: John T O’Brien, Hugh S Markus

Published in: BMC Medicine | Issue 1/2014

Login to get access

Abstract

Vascular factors are now established risk factors for cognitive decline, both for dementia and its two main subtypes: Alzheimer’s disease (AD) and vascular dementia. Their impact likely goes beyond causing an increase in concurrent vascular pathology, since they have been associated with increasing the risk of degenerative Alzheimer (plaque and tangle) pathology, either by increasing its rate of formation or reducing elimination from the brain, or a mixture of the two. A comprehensive series of reviews published in BMC Medicine, investigates the relationship between AD and cardiovascular diseases and risk factors from a clinical, pathological and therapeutic perspective. Whilst links between vascular factors and AD have clearly been demonstrated at both the clinical and pathological level, the nature of the relationship remains to be fully established and there is a lack of high quality treatment studies examining the extent to which vascular risk modification alters AD disease course. Further longitudinal mechanistic and therapeutic studies are required, especially to determine whether treatment of vascular risk can prevent or delay the onset of AD and/or reduce its rate of clinical progression.
Literature
1.
go back to reference Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E: Alzheimer’s disease. Lancet. 2011, 377: 1019-1031. 10.1016/S0140-6736(10)61349-9.CrossRefPubMed Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E: Alzheimer’s disease. Lancet. 2011, 377: 1019-1031. 10.1016/S0140-6736(10)61349-9.CrossRefPubMed
2.
go back to reference Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014, 370: 322-333. 10.1056/NEJMoa1304839.CrossRefPubMedPubMedCentral Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014, 370: 322-333. 10.1056/NEJMoa1304839.CrossRefPubMedPubMedCentral
3.
go back to reference Tosto G, Reitz C: Genome-wide association studies in Alzheimer’s disease: a review. Curr Neurol Neurosci Rep. 2013, 13: 1-7. 10.1007/s11910-013-0381-0.CrossRef Tosto G, Reitz C: Genome-wide association studies in Alzheimer’s disease: a review. Curr Neurol Neurosci Rep. 2013, 13: 1-7. 10.1007/s11910-013-0381-0.CrossRef
4.
go back to reference O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST: Vascular cognitive impairment. Lancet Neurol. 2003, 2: 89-98. 10.1016/S1474-4422(03)00305-3.CrossRefPubMed O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST: Vascular cognitive impairment. Lancet Neurol. 2003, 2: 89-98. 10.1016/S1474-4422(03)00305-3.CrossRefPubMed
5.
go back to reference Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997, 277: 813-817. 10.1001/jama.1997.03540340047031.CrossRefPubMed Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997, 277: 813-817. 10.1001/jama.1997.03540340047031.CrossRefPubMed
6.
go back to reference Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ: Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s coordinating centre. Brain. 2013, 136: 2697-2706. 10.1093/brain/awt188.CrossRefPubMedPubMedCentral Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ: Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s coordinating centre. Brain. 2013, 136: 2697-2706. 10.1093/brain/awt188.CrossRefPubMedPubMedCentral
7.
go back to reference Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Launer LJ: Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia Aging Study. Neurobiol Aging. 2000, 21: 57-62.PubMed Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Launer LJ: Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia Aging Study. Neurobiol Aging. 2000, 21: 57-62.PubMed
8.
go back to reference Weller RO, Preston SD, Subash M, Carare RO: Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther. 2009, 1: 6-10.1186/alzrt6.CrossRefPubMedPubMedCentral Weller RO, Preston SD, Subash M, Carare RO: Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther. 2009, 1: 6-10.1186/alzrt6.CrossRefPubMedPubMedCentral
11.
go back to reference Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O’Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, DeCarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, van Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M: Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013, 12: 822-838. 10.1016/S1474-4422(13)70124-8.CrossRefPubMedPubMedCentral Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O’Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, DeCarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, van Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M: Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013, 12: 822-838. 10.1016/S1474-4422(13)70124-8.CrossRefPubMedPubMedCentral
12.
go back to reference Smith AD, Smith SM, De Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H: Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010, 5: e12244-10.1371/journal.pone.0012244.CrossRefPubMedPubMedCentral Smith AD, Smith SM, De Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H: Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010, 5: e12244-10.1371/journal.pone.0012244.CrossRefPubMedPubMedCentral
13.
go back to reference Valenti R, Pantoni L, Markus HS: Treatment of vascular risk factors in patients with a diagnosis of Alzheimer disease; a systematic review. BMC Med. 2014, 12: 160.CrossRefPubMedPubMedCentral Valenti R, Pantoni L, Markus HS: Treatment of vascular risk factors in patients with a diagnosis of Alzheimer disease; a systematic review. BMC Med. 2014, 12: 160.CrossRefPubMedPubMedCentral
14.
go back to reference Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C: Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008, 7: 683-689. 10.1016/S1474-4422(08)70143-1.CrossRefPubMed Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C: Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008, 7: 683-689. 10.1016/S1474-4422(08)70143-1.CrossRefPubMed
15.
go back to reference Richard E, Kuiper R, Dijkgraaf M, Van Gool WA: Vascular care in patients with Alzheimer’s disease with cerebrovascular lesions-a randomized clinical trial. J Am Geriatr Soc. 2009, 57: 797-805. 10.1111/j.1532-5415.2009.02217.x.CrossRefPubMed Richard E, Kuiper R, Dijkgraaf M, Van Gool WA: Vascular care in patients with Alzheimer’s disease with cerebrovascular lesions-a randomized clinical trial. J Am Geriatr Soc. 2009, 57: 797-805. 10.1111/j.1532-5415.2009.02217.x.CrossRefPubMed
16.
go back to reference Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A: Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010, 74: 956-964. 10.1212/WNL.0b013e3181d6476a.CrossRefPubMed Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A: Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010, 74: 956-964. 10.1212/WNL.0b013e3181d6476a.CrossRefPubMed
17.
go back to reference O’Brien JT, Burns A, The BAP: Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2011, 25: 997-1019. 10.1177/0269881110387547.CrossRefPubMed O’Brien JT, Burns A, The BAP: Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2011, 25: 997-1019. 10.1177/0269881110387547.CrossRefPubMed
Metadata
Title
Vascular risk factors and Alzheimer’s disease
Authors
John T O’Brien
Hugh S Markus
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2014
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-014-0218-y

Other articles of this Issue 1/2014

BMC Medicine 1/2014 Go to the issue